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Abstract: Background and objectives: Fluid overload and central sleep apnea are highly prevalent
in patients with heart failure (HF). We performed this meta-analysis to assess the effects of
acetazolamide therapy on acid/base balance and apnea indexes. Methods: A literature search
was conducted using EMBASE, MEDLINE, and Cochrane Database from inception through
18 November 2017 to identify studies evaluating the use of acetazolamide in HF. Study results
were analyzed using a random effects model. The protocol for this systematic review is registered
with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017065401).
Results: Nine studies (three randomized controlled trials and six cohort studies) with a total of
229 HF patients were enrolled. After acetazolamide treatment, there were significant decreases in
serum pH (mean difference (MD) of −0.04 (95% CI, −0.06 to −0.02)), pCO2 (MD of −2.06 mmHg
(95% CI, −3.60 to −0.53 mmHg)), and serum bicarbonate levels (MD of −6.42 mmol/L (95% CI,
−10.05 to −2.79 mmol/L)). When compared to a placebo, acetazolamide significantly increased
natriuresis (standardized mean difference (SMD) of 0.67 (95% CI, 0.08 to 1.27)), and decreased the
apnea-hypopnea index (AHI) (SMD of −1.06 (95% CI, −1.75 to −0.36)) and central apnea index (CAI)
(SMD of −1.10 (95% CI, −1.80 to −0.40)). Egger’s regression asymmetry tests revealed no publication
bias with p = 0.20, 0.75 and 0.59 for analysis of the changes in pH, pCO2, and serum bicarbonate levels
with use of acetazolamide in HF patients. Conclusion: Our study demonstrates significant reduction
in serum pH, increase in natriuresis, and improvements in apnea indexes with use of acetazolamide
among HF patients.
Keywords: acetazolamide; diuretics; heart failure; sleep apnea; meta-analysis
1. Introduction
Heart failure affects 1–2% of the world population with a higher crude prevalence in high-income
countries [1]; however, its economic burden has grown globally. Fluid management is one of the
therapeutic keystones in assuring symptom and hospital admission control. Despite the ongoing
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development of advanced therapies, heart failure patients are facing new challenges due to a greater
prevalence of advanced concurrent chronic kidney disease (CKD) and diuretic resistance [2]. While loop
diuretics and thiazide diuretics are the primary diuretic therapy choice, other nephron tubular sites for
diuretic blockage have not been commonly utilized and could serve as another avenue for intervention.
Acetazolamide is a carbonic anhydrase inhibitor that blocks proximal tubular absorption of
sodium. Acetazolamide was first used in humans as a new diuretic with potential to treat congestive
heart failure [3] after it was found to be more potent and safer than sulfanilamide diuretic. Several case
studies in the 1950s that utilized acetazolamide in heart failure patients demonstrated successful
decongestive profiles [4–6]. Its use had been declining with the discovery of loop diuretics, which are
perceived as more potent [7]. However, there were new pieces of evidence showing that the ceiling
effect of acetazolamide was due to a compensatory increase of distal tubular Na-Cl co-transporter
mediated by decreased expression of pendrin, making dual use of acetazolamide and thiazide
diuretics a promising therapy for diuretic resistance [8,9]. Recently, Imiela et al. performed a
randomized control trial on the effect of acetazolamide on heart failure, showing a positive effect on
diuretic augmentation [10]. There are ongoing clinical trials that specifically investigate the effect of
acetazolamide on volume overload state; however, the results are still pending. Therefore, a systematic
review could provide a comprehensive background and understanding of current evidence in this
clinical scenario.
Acetazolamide has also been routinely used in altitude medicine [11] to prevent and treat fluid
retention and pulmonary edema by increasing diuresis, improving oxygenation and decreasing
periodic breathing patterns [12]. Patients with central sleep apnea (CSA) have demonstrated better
control of the apnea–hypopnea index (AHI) when treated with acetazolamide; however, its application
in heart failure patients with sleep disorders has not yet been implemented as common practice due to
concerns of urinary potassium wasting and the resulting potential arrhythmias [13]. As central sleep
disorder is a relatively common comorbidity in heart failure patients, with a reported rate of up to
30–50% in heart failure patients experiencing reduced left ventricular ejection fraction, acetazolamide
could be an additional therapeutic option that would not only help with the volume aspect of heart
failure but also the improvement of respiratory indices.
We performed a systematic review and meta-analysis to measure the overall potency of
acetazolamide in heart failure patients with a focus on acid/base alterations and alleviation of sleep
apnea indices.
2. Methods
2.1. Search Strategy and Literature Review
The protocol for this systematic review is registered with PROSPERO (International Prospective
Register of Systematic Reviews; no. CRD42017065401). A systematic literature search of EMBASE
(1988 to 18th November 2017), MEDLINE (1946 to 18th November 2017), and the Cochrane Database
of Systematic Reviews (database inception to 18th November 2017) was performed to identify studies
evaluating the use of acetazolamide in HF patients. The systematic literature review was performed
independently by two investigators (J.W. and C.T.) using the keywords and medical subject heading
(MeSH) terms of “acetazolamide” or “diamox”, and “heart failure” (provided in online Supplementary
Data S1). Additionally, a manual search for conceivably relevant articles using references of the
included articles was also performed. This study was conducted in accordance with the STROBE
(Strengthening the Reporting of Observational Studies in Epidemiology) [14] and the PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statements [15] as described in
online Supplementary Data S1.
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2.2. Selection Criteria
Eligible studies consisted of clinical trials or observational studies (cohort, case-control,
or cross-sectional studies) that assessed the effects of acetazolamide therapy on 1) acid/base balance
and 2) apnea indexes. The studies were included only if they provided data allowing for the calculation
of mean differences (MDs), standardized mean differences (SMDs), relative risks, or hazard ratios with
95% confidence intervals (CI). Retrieved articles were individually reviewed for eligibility by the two
investigators (J.W. and C.T.). Discrepancies were resolved by mutual consensus. The quality of each
included study was quantified via the Cochrane risk of bias tool [16]. The Newcastle-Ottawa quality
assessment scale was utilized to appraise the quality of study for observational studies [17].
2.3. Data Abstraction
A structured data collecting form was utilized to derive the following information from each
study: name of the first author, title, year of the study, publication year, country where the study was
conducted, demographic and characteristic data of heart failure patients, methods used to identify
heart failure, acetazolamide regimen and dosages, data on fluid and electrolytes, apnea indexes,
and adjusted effect estimates with 95% CI.
2.4. Statistical Analysis
Comprehensive Meta-Analysis software (version 3.3.070; Biostat Inc, Englewood, New Jersey,
USA) was used for the analyses. Adjusted point estimates from each included study were consolidated
by the generic inverse variance approach of DerSimonian and Laird, which designated the weight
of each included study based on its variance [18]. Given the likelihood of between-study variance,
we used a random-effect model rather than a fixed-effect model. Cochran’s Q test with I2 statistics were
applied to assess the between-study heterogeneity. An I2 value of 0% to 25% indicates insignificant
heterogeneity, 26% to 50% low heterogeneity, 51% to 75% moderate heterogeneity and 76% to 100%
high heterogeneity [16,19]. The Egger test was used to assess the presence of publication bias [20].
3. Results
A total of 614 potentially eligible articles were identified using our search strategy. After excluding
571 articles that did not fulfill inclusion criteria on the basis of type of article, study design, population,
and outcome of interest, 43 articles were left for full-length review (Supplementary Data S1). Thirty-four
of the final 43 articles were additionally excluded from full-length review, as shown in Figure 1.
Thus, the final analysis included nine articles consisting of three randomized controlled trials and six
cohort studies with a total of 229 HF patients. The literature retrieval, review, and selection process are
demonstrated in Figure 1.
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The characteristics and quality assessment of the included studies are presented in Tables 1 and 2.
Table 1 describes the main characteristics of experimental studies that utilized acetazolamide as a
treatment agent in patients with heart failure. The two studies from Javaheri et al. [21,22] used
acetazolamide as an experimental drug and monitored several sleep disorder parameters. Both studies
shared similar methodologies. The third study by Imiela et al. [10] was one of the first randomized
controlled trials that was dedicated to heart failure outcomes including urine output and clinical
measurements. Table 2 summarizes important descriptions of observational studies that focused
on acetazolamide in various settings of heart failure patients. It is of note that three out of six were
performed prior to the era of evidence-based medicine; therefore, case definition and measured
parameters may deviate from the other studies. Amongst the other three studies that were performed
more recently, all share similar quality of case selection and ascertainment of exposure (diuretics).
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Table 1. Main characteristics of the RCTs included in the meta-analysis of acetazolamide therapy in heart failure patients.
Study (Author,
Year) Javaheri, 2006 [21] Javaheri, 2014 [22] Imiela, 2017 [10]
Method
Study design RCT, double-blind cross-over placeboand acetazolamide
RCT, double-blind cross-over placebo
and acetazolamide RCT, single-center, unblinded
Total number 12 6 20
Patient sample Stable systolic heart failure Stable systolic heart failure Patient hospitalized with chronic heartfailure exacerbation
CHF definition
Systolic HF (EF < 35%) with
Cheyne-Stokes breathing and AHI >
15/h
Systolic heart failure and CSA (AHI >
15/h) EF < 50%, signs of volume overload
Acetazolamide
dosing
Acetazolamide 3.5–4 mg/kg + KCL
60 meq
Acetazolamide 3.5–4 mg/kg + KCL
60 meq
Once daily (dose-adjusted to body weight,
range from 250 mg to 500 mg) as add-on
diuretics to furosemide
Description RCT about acetazolmide butdesigned for sleep disorder
RCT about acetazolmide but
designed for sleep disorder RCT dedicated to acetazolamide
Cochrane risk of
bias
Selection Low Low Low
Performance Low Low High
Detection Low Low High
Attrition Low Low Low
Reporting Low Low Low
Other Low Low Low
Abbreviations: RCT, randomized controlled trial; CHF, congestive heart failure; EF, ejection fraction; AHI, apnea-hypopnea index; CSA, central sleep apnea; KCL, potassium chloride.
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Table 2. Main characteristics of cohort studies included in meta-analysis of acetazolamide therapy in heart failure patients.
Study (Author, Year) Schwartz, 1955 [23] Mauck, 1957 [24] Khan, 1980 [25] Fontana, 2011 [26] Apostolo, 2014 [27] Verbrugge, 2015 [28]
Method
Study design Cohort, time series Cohort, time series Cohort, time series Cohort Cohort Cohort
Total number 17 14 74 12 20 54
Patient sample Severe CHF with corpulmonale Stable CHF
Hospitalized
decompensated CHF
CHF with periodic
breathing
CHF with periodic
breathing
Hospitalized decompensated
CHF
CHF definition
Clinical diagnosis with
severe pulmonary disease,
with ECG or Xray change
of right heart enlargement
or strain
Fully digitalized ambulatory
CHF on 1 gm diet, mostly
edema free. Wash out from
other diuretics for two weeks
Patients diagnosed with
CHF that failed treatment
with furosemide,
spironolactone and salt
restriction
EF < 50%, with AHI > 15 EF < 40%, with periodicbreathing during exercise
At least three signs of volume
overload, EF < 45%
Acetazolamide
dosing 1–1.5 gm over 24 h 250 mg qday
250 mg qid (1 g per day),
used as a replacement of
furosemide
250 mg po bid for 4 days 500 mg IV and prolonged 2gm over 24 h 250 mg qday
Description
Using acetazolamide to
treat patient with cor
pulmonale and
respiratory acidosis
Studying effect of
acetazolamide in ambulatory
CHF, aiming at electrolyte
values during therapy
Using acetazolamide
instead of furosemide for
diuresis
Measure breathing
parameters with ABG
analysis before and after
acetazolamide treatment
Measured respiratory
pattern before and after
acetazolamide treatment
Cohort finding predictor of
natriuresis
Quality
assessment
(Newcastle-
Ottawa scale)
Selection 2 2
2
- Independent validation
- Obvious series of cases
3
- Using cohort of CHF
- Non-exposed cohort is self
prior to acetazolamide
- Secure record
3
- Using cohort of CHF
- Non-exposed cohort is self
prior to acetazolamide
- secure record
3
- True representation of CHF
- Same community of control
- Secure record
Comparability 1 1
1
- Study controls by using
prior-self prior to treatment
with acetazolamide
1
- Study controls by using
prior-self prior to treatment
with acetazolamide
1
- Study controls by using
prior-self prior to treatment
with acetazolamide
2
- Using multivariate analysis
and still showed acetazolamide
as important factor
Outcome 1 1 1-Secure record (hospital) NA NA NA
Exposure NA NA NA
2
- Record linkage
- Long follow up
2
- Record linkage
- Long follow up
3
-Record linkage
- Long follow up
- Complete follow up of all
subjects
Abbreviations: CHF, congestive heart failure; EF, ejection fraction; AHI, apnea–hypopnea index; ECG, electrocardiogram; IV, intravenous; ABG, arterial blood gas; NA, not applicable.
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3.1. Effects of Acetazolamide on Acid/Base Balance in HF Patients
After acetazolamide treatment, there were significant decreases in serum pH (mean difference
(MD) of −0.04 (95% CI, −0.06 to −0.02), I2 = 65%, Figure 2A), pCO2 (MD of −2.06 mmHg (95% CI,
−3.60 to −0.53 mmHg), I2 = 0%, Figure 2B) and serum bicarbonate levels (MD of −6.42 mmol/L
(95% CI, −10.05 to −2.79 mmol/L), I2 = 95%, Figure 2C). This finding confirmed the expected effects
of acetazolamide use in our population of interest. The changes of pCO2 appeared to be less robust
than serum bicarbonate level as reflected by a wider confidence interval in each study. This may be
due to variation in the time of blood specimen collection, allowing more variation in the respiratory
compensation in response to induced metabolic acidosis. When compared to a placebo, acetazolamide
significantly increased natriuresis (standardized mean difference (SMD) of 0.67 (95% CI, 0.08 to 1.27)),
I2 = 0%, Figure 3).
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3.2. Effects of Acetazolamide on Apnea Indexes
When compared to a placebo, acetazolamide treatment significantly reduced the apnea-hypopnea
index (AHI) (SMD of −1.06, (95% CI, −1.75 to −0.36), I2 = 0%, Figure 4A) and central apnea index
(CAI) (SMD of −1.10, (95% CI, −1.80 to −0.40)), I2 = 0% Figure 4B), respectively. It is important to note
that both of the studies included in this analysis came from the same investigator with a very similar
study protocol used in each study. As measurement of sleep parameters required an elaborate setting
to be quantified, other studies did not contain the data required to be included in the meta-analysis.
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3.3. Sensitivity Analysis
Sensitivity analysis was performed by excluding one study at a time to investigate the effect of
each study on the pooled MD and SMD for each outcome assessed. The pooled effect estimate from
the sensitivity analysis remained essentially unchanged.
3.4. Evaluation for Publication Bias
We found no publication bias as assessed by the Egger’s regression asymmetry test with p = 0.20,
0.75 and 0.59 for analysis of the changes of serum pH, pCO2, and serum bicarbonate levels with use of
acetazolamide in HF patients, respectively. Since a limited number of included studies evaluated the
changes of AHI and CAI, the power of the test is too low to evaluate the publication bias.
4. Discussion
In this meta-analysis, we consolidated the effects of using acetazolamide in populations of heart
failure patients. By inducing bicarbonaturia at the level of the proximal tubules, acetazolamide led
to a modest decrease in serum bicarbonate (MD of 6.42 mmol) without a considerable disruption
of pCO2 and pH in this patient population. This suggests that an acetazolamide-induced metabolic
acidosis could assist respiratory compensation even in patients with heart failure. There is a reasonable
need for caution towards medications that can cause an abrupt change in pH due to their potential
to cause an arrhythmogenic state. Our study, however, showed that acetazolamide use in heart
failure only caused minor changes in serum pH (MD of 0.04), making it a reasonable agent to use in
patients who have developed contraction alkalosis from diuresis. In addition, acetazolamide increased
natriuresis compared to a placebo, thus supporting prior evidence that showed its use as an adjunct
to other diuretics [8–10]. One important note for the pharmacodynamic profile of acetazolamide
was the development of tolerance after consecutive days of daily administration [29], which resulted
in decreased natriuresis and potassium excretion after 48–72 h. The authors suggested limiting
acetazolamide use to no more than three to four days a week or for less than two consecutive days
at a time in order to sustain its desired diuretic properties. The mechanism of this phenomenon was
unclear and it was unknown whether the effect of acid-base changes may also be affected, suggesting
a topic for further experimental research.
Acetazolamide was also shown to improve apnea–hypopnea index and central apnea index in
our study. This finding expanded the potential use of acetazolamide in heart failure patients, as sleep
apnea is a common comorbidity that is often exacerbated with heart failure decompensation [30].
While controversy existed around the risk or benefit of adaptive servo-ventilation (ASV) use in the
heart failure population, continuous positive airway pressure (CPAP) is well accepted as a modality
of treatment for obstructive sleep apnea (OSA) in the heart failure population. As compliance with
CPAP use remains a substantial barrier to effective treatment of sleep apnea, acetazolamide could
potentially serve as an alternative therapeutic modality for this patient population. The mechanism
of acetazolamide effect on sleep indices is still unclear. Prior studies have found evidence that
acetazolamide paradoxically improved apnea indices despite augmenting hypercapnic ventilatory
response, (HCVR) which was thought to be the main pathophysiology of central sleep apnea [22].
Authors have proposed other mechanisms including changes in O2 and CO2 chemoreceptor sensitivity
as the possible explanation of how acetazolamide led to more favorable apnea indices. It is important to
note that in two of the studies that we analyzed, the reduction of AHI was not associated with increased
diuresis or an improved cardiac status, suggesting that the effect of acetazolamide in optimizing sleep
indices may be independent of the patient’s volume status. Future studies exploring the effect of
acetazolamide on sleep indices after diuresis has achieved the desired volume status in heart failure
patients, and whether the independent beneficial effect persists, will be important. When compared to
the non-heart failure central sleep apnea patients, several studies addressed the effect of acetazolamide
on CSA and OSA. There was a general trend of acetazolamide improving the CSA sleep parameter and
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sleep-related symptoms, but there conflicting evidence on the effect of OSA sleep parameter. A recent
publication by Aurora et al. [31] proposed acetazolamide as an option of CSA for both the heart
failure and the non-heart failure patient but acknowledged the potential side effect of the medication.
Given the complexity of non-heart failure CSA patients with persistent of CO2 receptor reset [32],
ongoing research exploring the impact of acetazolamide in a CHF patient may benefit from additional
outcome adjudication after acetazolamide therapy was interrupted.
Potential deleterious effects of acetazolamide include metabolic acidosis, which could transiently
increase the sympathetic response of heart failure [21]. It is also possible that hyperventilation as
a result of acetazolamide use could lead to increased fatigability of respiratory muscles during the
treatment period. Several early studies of acetazolamide reported side effects such as nausea, vomiting,
paresthesia, dizziness, and muscle cramps. These symptoms were attributed to electrolyte and
acid-base shifts that occurred either from diuresis or were a direct effect of the carbonic anhydrase
inhibition on nerve cells [33]. Potassium monitoring and appropriate supplementation will be critical
in the effective use of acetazolamide, as reflected in multiple prior studies that included potassium
supplementation in the study protocol. In the study from Javaheri 2006 which utilized a slightly higher
dose of acetazolamide, one participant reported shortness of breath during the study. The author
proposed that the effect was due to the dosage of the medication being higher than what would be
used in clinical practice. None of the patients in the study reported cases of paresthesia.
There are several limitations to this meta-analysis. First, the quality of the observational studies
was limited as many were performed before the era of modern evidence-based medicine. However, the
three selected studies described their protocol meticulously, and by further utilizing the same patients
for both the control and exposure population, it resembled a time series methodology. Second, the three
cohort studies included were very well-designed studies but were not primarily looking at the effects
of acetazolamide on the outcome of our interest; this would introduce potential bias by analyzing
previous reported secondary data. On the other hand, the data from the three randomized control
trials were of high quality given its sole use of acetazolamide as the main intervention. Only one study
did not provide blinding for acetazolamide use, which likely could have led to detection bias in the
subjective outcome (dyspnea scale) of the study. However, our pooled data of urinary sodium excretion
should be minimally affected. In addition, we performed an additional search of the literature to
cover recently published articles up to the time of publication. We identified seven other items [34–40],
two of which would qualify for our screening criteria. However, both of the articles did not contain our
outcome of interest even though part of the studies involved the usage of acetazolamide. Thus, future
large-scale clinical trials are required to confirm these effects of acetazolamide therapy on acid/base
balance and apnea indexes.
In summary, our systematic review and meta-analysis suggest that acetazolamide may have a
potential beneficial effect in select heart failure patients by reducing serum bicarbonate level and
augmenting natriuresis with only slight changes in serum pH and pCO2. Acetazolamide also helped to
reduce sleep apnea indices, expanding its potential use for sleep apnea in the heart failure population.
Further studies to explore the mechanism, safety, and beneficial effects of acetazolamide when used in
conjunction with other diuretics would be an important next step prior to its widespread adoption in
the clinician’s armamentarium.
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